IBJNews

Lilly tops analyst expectations despite shrinking profit, revenue

Back to TopCommentsE-mailPrintBookmark and Share

First-quarter profit fell 4 percent at Eli Lilly and Co., but the Indianapolis-based drugmaker easily beat the expectations of Wall Street analysts.

That prompted Lilly to boost its full-year profit forecast by 5 cents to 10 cents per share.

Lilly’s revenue and profit have been falling after it lost patent protection on two blockbuster drugs: the cancer drug Gemzar in late 2010 and the antipsychotic Zyprexa in late 2011.

But the company said sales in other parts of its business—including the antidepressant Cymbalta, the blood thinner Effient, animal health products and in China—all grew by 20 percent or more

Lilly’s quarterly revenue totaled $5.6 billion, down 4 percent from the previous year. Wall Street analysts were expecting revenue of $5.36 billion, according to a survey by Thomson Reuters.

"Notwithstanding the negative effect of the expiration of the Zyprexa patent in the U.S. and many international markets, Lilly demonstrated strong underlying growth in other products and key regions,” Lilly CEO John Lechleiter said in a prepared statement.

Lilly’s profit in the first quarter totaled $1.01 billion, or 91 cents per share, down from $1.06 billion, or 95 cents per share, in the same quarter a year ago.

Wall Street analysts were expecting 78 cents per share in the most recent quarter, according to a Thomson Reuters.

The decline in profit was actually much larger than it seems. A year ago, Lilly booked some one-time charges for research deals with other companies and for reductions in personnel. Excluding all such charges in both years, Lilly’s per-share profit would have fallen by nearly 26 percent, from $1.24 per share in the first quarter a year ago to 92 cents per share this year.

For all of 2012, Lilly now expects per-share profit in a range of $3.15 to $3.30, excluding a penny-per-share charge taken in the first quarter for a one-time restructuring move. In January, Lilly had predicted it would earn 2012 profit of $3.10 per share to $3.20 per share.

Lilly shares were up 52 cents, or 1.3 percent, in late-morning trading, to $40.48 each. They are down 3.1 percent since the beginning of the year.

ADVERTISEMENT

  • Zyprexa issues
    Eli Lilly did make $65 billion on Zyprexa and they still expect to capture 20% of the US market as well as a billion year on ZyprexaXR.


    The patent only expires in the US and some Euro,Lilly announced they have an *authorized* distributor of generic Zyprexa.

    I am keenly interested in how they resolve remaining Zyprexa litigation.

    PTSD treatment for Veterans found ineffective.
    Zyprexa can cause diabetes.
    I took Zyprexa Olanzapine a powerful Lilly schizophrenic drug for 4 years it was prescribed to me off-label for post traumatic stress disorder was ineffective costly and gave me diabetes.
    *FIVE at FIVE*
    The Zyprexa antipsychotic drug,whose side effects can include weight gain and diabetes, was sold to Veterans,children in foster care, elderly in nursing homes.
    *Five at Five* was the Zyprexa sales rep slogan, meaning *5mg dispensed at 5pm would keep patients quiet*.

    *Tell the truth don't be afraid*-- Daniel Haszard
    FMI zyprexa-victims(dot)com



Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. OK Larry, let's sign Lance, shore up the PG and let's get to the finals.

  2. A couple of issues need some clarification especially since my name was on the list. I am not sure how this information was obtained and from where. For me, the amount was incorrect to begin with and the money does not come to me personally. I am guessing that the names listed are the Principal Investigators (individual responsible for the conduct of the trail) for the different pharmaceutical trials and not the entity which receives the checks. In my case, I participate in Phase II and Phase III trials which are required for new drug development. Your article should differentiate the amount of money received for consulting, for speaking fees, and for conduct of a clinical trial for new drug development. The lumping of all of these categories may give the reader a false impression of physicians just trying to get rich. The Sunshine Law may help to differentiate these categories in the future. The public should be aware that the Clinical Trial Industry could be a real economic driver for Indiana since these revenues supports jobs and new job creation. Nationally, this account for 10-20 billion which our State is missing out on to a large degree. Yes, new drug and technology development has gotten most of the attention (e.g. CTSI, BioCrossroads, etc.) However, serious money is being left on the table by not participating in the clinical trials to get those new drugs and medical devices on the market!!!! I guess that this is not sexy enough for academia.

  3. The address given for the Goldfish Swim Club is the Ace Hardware, is it closing?

  4. Out of state management and ownership. If Kite controlled it, everything would be leased. Of course, due to the roundabout, there is limited access to the south side of 116th now also. Just have to go down to the light.

  5. Hey smudge, You're opposed to arresting people for minor crimes? Sounds great! We should only focus on murders and such, right? Let's stand around and wait until someone shoots someone before we act. Whatever we do, we should never question anyone, frisk anyone, or arrest anyone unless they are actively engaged in shooting or stabbing. Very sound!

ADVERTISEMENT